US Pharma MarketingCharles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy
Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to its CEO Birgit Girshick, other companies are likely considering doing the same thing. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the…
Three months ago, Charles River Laboratories announced it would shed its manufacturing unit, which has a focus on cell and gene therapies. And, according to its CEO Birgit Girshick, other companies are likely considering doing ...
Source: Endpoints News